<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>1998</study_start_year><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2003609</full_dataset_link><study_start_month>9</study_start_month><keyword>Recurrent rectal cancer</keyword><keyword>Recurrent colon cancer</keyword><keyword>Stage IV rectal cancer</keyword><keyword>Eniluracil</keyword><keyword>Stage III rectal cancer</keyword><keyword>Stage I colon cancer</keyword><keyword>Stage I rectal cancer</keyword><keyword>Stage II colon cancer</keyword><keyword>Stage IV colon cancer</keyword><keyword>Stage III colon cancer</keyword><keyword>Stage II rectal cancer</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer</name><description>RATIONALE: Eniluracil may increase the effectiveness of chemotherapy by blocking tumor enzymes that break down chemotherapy drugs.
PURPOSE: Randomized phase II trial to determine the effectiveness of eniluracil followed by surgery in treating patients who have primary or metastatic colorectal cancer.</description><dates><creation>1998-09-15</creation></dates><accession>2003609</accession><cross_references><ClinicalTrials___gov>NCT00004195</ClinicalTrials___gov></cross_references></HashMap>